Cancer Research Institute Announces Fall 2024 CRI Irvington and Immuno-Informatics Fellows Advancing Cancer Immunotherapy

The Cancer Research Institute (CRI) is proud to announce its Fall 2024 class of CRI Irvington Postdoctoral Fellows and Immuno-Informatics Fellows, supporting pioneering scientists conducting transformative research in cancer immunotherapy. The CRI Irvington Postdoctoral Fellowship supports the training of exceptional postdoctoral researchers, preparing them to become future leaders in immuno-oncology. These exceptional researchers are investigating novel therapeutic strategies to harness the immune system against cancer, with projects spanning CAR T-cell therapy, tumor metabolism, computational immunology, and immune regulation. 

“Our fellows represent the future of cancer immunotherapy, tackling some of the most complex challenges in the field with bold, innovative approaches,” said Dr. Alicia Zhou, CRI’s Chief Executive Officer. “Their research will not only expand our fundamental understanding of cancer immunology but also bring us closer to new, more effective treatments for patients worldwide.” 

Fall 2024 CRI Irvington Postdoctoral Fellows 

(Supporting early-career scientists in their training and advancing immuno-oncology research) 

• Hannah Bell, MD, PhD – University of Michigan 

• Jesse Boumelha, PhD – Icahn School of Medicine at Mount Sinai 

• Joseph Collins, PhD – Boston Children’s Hospital 

• Liuhui Fu, PhD – NYU Grossman School of Medicine 

• Mingeum Jeong, PhD – Weill Cornell Medicine 

• Anukriti Mathur, PhD – UMass Chan Medical School 

• Kat Mueller, PhD – Children’s Hospital of Philadelphia 

• Parasvi Patel, PhD – Massachusetts General Hospital 

• Harrison Sudholz, PhD – University of California, Berkeley 

• Aldo Ummarino, MD, PhD – Boston Children’s Hospital 

• Rosa Vincent, PhD – Baylor College of Medicine 

• Peter Wang, PhD – Massachusetts General Hospital 

Fall 2024 CRI Immuno-Informatics Fellows 

(Bridging quantitative and biological sciences to drive the next breakthroughs in cancer immunotherapy) 

• Anca Apavaloaei, PhD – Weill Cornell Medicine 

• Hratch Baghdassarian, PhD – Massachusetts Institute of Technology 

• Liam Hendrikse, PhD – University Health Network (Canada) 

• Seongyeol Park, MD, PhD – Stanford University 

Since 1953, CRI has been at the forefront of advancing cancer immunotherapy by investing in the people driving scientific breakthroughs, deepening our understanding of biology, and leveraging cutting-edge data to accelerate discovery. With this new class of fellows, CRI continues its commitment to transforming cancer treatment through innovative research that harnesses the power of the immune system. 

—

Media Contact: 

Dustin Etheridge 

Director of Communications – Cancer Research Institute 

[email protected]